Screener
CRISPR Therapeutics CRSP EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Net loss | (122,931) | (135,996) |
| Foreign currency translation adjustment | (32) | 41 |
| Unrealized (loss) gain on marketable securities | (6,730) | 2,254 |
| Comprehensive loss | $(129,693) | $(133,701) |
| Net loss per common share — basic | $(1.28) | $(1.58) |
| Basic weighted-average common shares outstanding | 96,051,228 | 85,938,720 |
| Net loss per common share — diluted | $(1.28) | $(1.58) |
| Diluted weighted-average common shares outstanding | 96,051,228 | 85,938,720 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's EPS (diluted)?
- CRISPR Therapeutics (CRSP) reported EPS (diluted) of -$1.28 in Q1 2026.
- How has CRISPR Therapeutics's EPS (diluted) changed year-over-year?
- CRISPR Therapeutics's EPS (diluted) increased by 19.0% year-over-year, from -$1.58 to -$1.28.
- What is the long-term trend for CRISPR Therapeutics's EPS (diluted)?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's EPS (diluted) has grown at a -11.8% compound annual growth rate (CAGR), from -$8.36 to -$6.50.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about CRISPR Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude